

Supplementary Table S6. Individual clinical and laboratory profile of RA patients naïve to b/tsDMARDs initiating TNFi (Cohort 5).

Clinical parameters	RA naïve patients starting TNFi (n=125)	3-months (n=112)	6-months (n=102)	12-months (n=78)
Male/Female (n/n)	29/96	-	-	-
Age, years (mean ± SD)	52.50 ± 11.87	-	-	-
Disease evolution, years (mean ± SD)	8.77 ± 7.57	-	-	-
TJC (mean ± SD)	7.29 ± 5.97	2.92 ± 4.82****	2.20 ± 4.23****	2.01 ± 4.45****
SJC (mean ± SD)	5.30 ± 5.34	1.52 ± 3.34****	1.02 ± 2.72****	1.03 ± 3.62****
DAS28-CRP (mean ± SD)	4.62 ± 1.25	2.99 ± 1.27****	2.79 ± 1.20****	2.67 ± 1.23****
SDAI (mean ± SD)	27.53 ± 13.83	13.97 ± 11.27****	12.03 ± 9.81****	11.07 ± 11.21****
CDAI (mean ± SD)	25.69 ± 12.80	13.01 ± 11.18****	11.16 ± 9.66****	10.27 ± 11.03****
HAQ (mean ± SD)	1.58 ± 0.73	1.38 ± 0.68	1.05 ± 0.71	0.60 ± 0.65
Smoking (n, %)	38, 30.40%	-	-	-
Hypertension (n, %)	28, 22.40%	-	-	-
Laboratory parameters				

CRP, mg/mL (mean ± SD)	18.39 ± 29.15	9.23 ± 18.41***	7.81 ± 10.80***	7.06 ± 8.07***
ESR, mm/h (mean ± SD)	23.88 ± 22.37	16.01 ± 17.59****	18.45 ± 17.83*	21.81 ± 22.18
ACPAs positivity (n, %)	94, 75.20%	25, 20.00%	58, 46.40%	44, 35.20%
RF positivity (n, %)	101, 80.80%	74, 59.20%	70, 56.00%**	56, 44.80%
Treatments				
Corticosteroids (n, %)	98, 78.40%	-	-	-
NSAIDs (n, %)	104, 83.20%	-	-	-
cDMARDs (n, %)	120, 96.00%	-	-	-

TJC (Tender Joint Count); SJC (Swollen Joint Count); DAS28-CRP (Disease Activity Score); SDAI (Simplified Disease Activity Index); CDAI (Clinical Disease Activity Index); HAQ (Health Assessment Questionnaire); CRP (C-reactive protein); ESR (Erythrocyte sedimentation rate); ACPA (Anti-citrullinated protein antibodies); RF (Rheumatoid Factor); NSAID (Non-steroidal anti-inflammatory drug); cDMARD (Conventional DMARDs). Statistical significance levels respect to baseline time were designated as follows: (****) <0.0001 p-value; (***) <0.001 p-value; (**) <0.01 p-value; (*) <0.05 p-value.